Month: March 2022

Digerati Technologies (DTGI) – A Surprising Reaction To A Solid Quarter; Raising Price Target

Posted on by Admin

Tuesday, March 22, 2022

Digerati Technologies (DTGI)
A Surprising Reaction To A Solid Quarter; Raising Price Target

Digerati Technologies, Inc. (OTCQB: DTGI) is a telecom and technology provider of diverse, carrier-grade, Only in the Cloud™ communication and network solutions including Unified Communication as a Service, cloud telephony, cloud WAN, cloud call center, cloud mobile, and delivery of digital oxygen on its fiber/mobile broadband network. Digerati has developed a robust integration platform to fuel mergers and acquisitions in a highly fragmented market as it delivers flexible, cost-effective services with enterprise-grade quality and reliability. A multi-year recipient of Deloitte’s Fast500 and Fast50 Awards for one of the fastest growing technology companies in North America, Digerati has become an expert at successfully merging and managing subsidiary operations since 2015. The Company’s impressive tech-stack serves 28,000 business users on its platform and its dynamic channel program includes over 300 channel partners that serve as a conduit for sales growth. Digerati has continuously increased customer adoption while serving diverse industries including Healthcare, Banking, Financial Services, Legal, Real Estate, and Construction. Digerati currently has a strong platform for growth throughout Texas and Florida, the 2nd and 4th largest state economies by GDP in the U.S. The Company’s clean and clear fundamentals, combined with its clearly defined growth plan, disciplined acquisition strategy and seasoned leadership team is expected to increase shareholder value as it enters the next phase of its corporate development plan. For more information, please visit www.digerati-inc.com.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Solid Q2 results.  Digerati reported better than expected fiscal second quarter end January 31 results, with total company revenues of $4.019 million, versus our $3.790 million estimate. Adj. EBITDA was also better than expected at $0.364 million versus our $0.309 million estimate. The results benefited from one month contribution from the Skynet acquisition, but results were better than expected after adjusting for that contribution.

    Executing the roll-up strategy.  The company has completed two acquisitions since the start of the year, SkyNet Telecom and Next Level. These acquisitions have augmented its customer reach in Texas and expanded operations into California. and now serves over 4,000 business customers and 45,000 users …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Release – BioSig Technologies Inc. Announces $3 Million Financing with Family Office

Posted on by Admin



BioSig Technologies, Inc. Announces $3 Million Financing with Family Office

News and Market Data on BioSig Technologies

 

Westport, CT, March 22, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it entered in a definitive purchase agreement for the sale of  $3 million of the Company’s common stock and warrants lead by a family office that has deep expertise in small cap emerging growth investing.  The closing of the offering is expected to occur on or about March 23, 2022, subject to the satisfaction of customary closing conditions.

Under the terms of the financing agreement, the Company will issue 2,611,739 shares of its common stock at a price of $1.15 per share and warrants to purchase 2,611,739 shares of the Company’s common stock at $1.40 per share.

BioSig intends to use the net proceeds from the offering to fund working capital and continue commercialization activities related to the PURE EP™ System.  This funding and its existing capital should provide sufficient operating capital for BioSig to execute its current business plan.

The offering is being made only by means of a prospectus supplement and accompanying base prospectus. The Company has filed a shelf registration on Form S-3 (File No. 333-251859) (including a base prospectus) with the U.S. Securities and Exchange Commission (“SEC”), which was declared effective on January 12, 2021. A final prospectus supplement and accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying base prospectus for the offering may also be obtained, when available, by contacting BioSig Technologies, Inc., 55 Greens Farms Road, Westport, CT 06880, Attention: Lora Mikolaitis; lmikolaitis@biosigtech.com. 

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the closing of the offering, (ii) the use of proceeds for the offering, (iii) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (iv) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (v) difficulties in obtaining financing on commercially reasonable terms; (vi) changes in the size and nature of our competition; (vii) loss of one or more key executives or scientists; and (viii) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119

Source: BioSig Technologies, Inc.

Release – Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

Posted on by Admin



Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

Research, News, and Market Data on Cocrystal Pharma

 

BOTHELL, Wash., March 22, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in the 2022 Virtual Growth Conference, presented by Maxim Group and hosted by M-Vest, being held March 28-30, 2022. Those interested in attending the virtual conference can register here.

A pre-recorded company presentation will be available on the M-Vest platform for 72 hours beginning March 28 at 9:00 a.m. Eastern time and can be accessed here. An archived webcast of the presentation will be available on the IR Calendar page of the company website.

Maxim Group LLC is a leading full-service investment bank, securities and wealth management firm headquartered in mid-town Manhattan and is a registered broker-dealer with the SEC and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA and SIPC. M-Vest is a division of Maxim Group LLC that serves to allow investors to access investment opportunities online and to provide a digital community built for issuers, investors, and thought leaders to share information.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com

Source: Cocrystal Pharma, Inc.

Release – Comstock Announces Notice of 2021 Year End Webcast

Posted on by Admin



Comstock Announces Notice of 2021 Year End Webcast

Research, News, and Market Data on Comstock Mining

 

VIRGINIA CITY, Nev., March 22, 2022 (GLOBE NEWSWIRE) — Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced that it will host a conference call on Tuesday, March 29, 2022, at 8:00 a.m. Pacific Daylight Time (11:00 a.m. Eastern Daylight Time) to report its 2021 Year End results and provide a business update. The webcast will include a moderated question and answer session after the Company’s prepared remarks. Please click the link below to register in advance and join the event 10 to 15 minutes prior to the scheduled start time. After registering, you will receive a confirmation email containing information about joining the Webcast.

March 29, 2022, 08:00 AM Pacific Daylight Time / 11:00 AM Eastern Daylight Time (US and Canada)

Topic: Comstock’s Year End 2021 Results and Business Update

Please click here to register in advance for this webcast.

About Comstock Mining Inc.
Comstock Mining Inc. (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting massive supplies of under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complimentary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstockmining.com.

Forward-Looking Statements
This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future changes in our research and development; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; and future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, taxes, earnings and growth. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in reports that we file with the Securities and Exchange Commission, including Item 1A, “Risk Factors” in our most recently-filed Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, mercury remediation and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration or mercury remediation, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with mercury remediation, metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; ability to achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology, mercury remediation technology and efficacy, quantum computing and advanced materials development, and development of cellulosic technology in bio-fuels and related carbon-based material production; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither this press release nor any related call or discussion constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

Contact information:    
Comstock Mining Inc.
P.O. Box 1118
Virginia City, NV 89440
ComstockMining.com		 Corrado De Gasperis
Executive Chairman & CEO
Tel (775) 847-4755
degasperis@comstockmining.com		 Zach Spencer
Director of External Relations
Tel (775) 847-5272 Ext.151
questions@comstockmining.com

SPACtrac Report – Forbes Media Group: CEO Discusses Strategy; Raise Price Target

Posted on by Admin

Tuesday, March 22, 2022

Forbes Media Group: CEO Discusses Strategy; Raise Price Target

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Patrick McCann, Research Associate, Noble Capital Markets, Inc.

Refer to end of report for Analyst Certification & Disclosures

C-suite interview highlights. Forbes CEO, Mike Federle, recently participated in Channelchek’s C-suite Interview series. This report highlights some of the topics discussed in the interview, such as the company’s recent favorable results and outlook, and the strategic investment in the Forbes SPAC merger by blockchain titan, Binance. The full interview may be viewed here.

Revising estimates upwards. The company’s full year results outperformed management’s forecast, achieving revenue and adj. EBITDA targets for 2022 in 2021. As a result, we are applying management’s forecasted growth rates to 2021 full year results to arrive at updated 2022 and 2023 estimates for revenue and adj. EBITDA, detailed later in this report.

Strategic investor joins merger deal. Forbes recently announced that Binance has committed to a $200 million investment in the SPAC merger that will take Forbes public. The investment by Binance will also give Forbes a valuable partnership due to Binance’s blockchain technology expertise. Forbes will be able to leverage that expertise to enhance the value of the recourses Forbes provides to investors who are interested in learning about digital assets.

Forbes CEO to participate at Noblecon 18. Forbes CEO, Mike Federle, will be participating in a panel about blockchain and cryptocurrency technology at NobleCon 18. Forbes will also be giving a company presentation at the conference, which is takes place at the Hard Rock Hotel in Hollywood, FL from April 19-21, 2022. To register for the conference, click here.

Raising price target. Near current levels, the OPA shares trade at 9.5 times Enterprise Value to expected 2022 EBITDA and 7.6 times EV to 2023 EBITDA estimates, which reflects upwardly revised EBITDA forecasts following the company’s strong recent results. We are revising our price target to $16 from $14.

Investment Summary

Forbes Media Group CEO, Mike Federle, recently participated in Channelchek’s C-suite Interview series. In the interview, he discussed the company’s strong fundamentals, favorable results and outlook, as well as the recent strategic investment in the Forbes SPAC merger by blockchain titan, Binance. The full interview can be found here.

Regarding the favorable results, the company’s strong Q4 revenue growth of 51% year-over-year capped off a successful 2021. For the full year, revenue increased 40% to $259 million, which was 15% above management’s most recent projection of $225 million. Full year adj. EBITDA of $60 million topped management’s estimate of $46 million by 31%. Figure #1 Operating Results illustrates the company’s results over the last 3 years. Notably, 2021 profit margins were well above the previous 2 years and revenue exceeded 2019 pre-pandemic levels.

Figure #1 Operating Results

Source: Company filings

The company’s growth in 2021 provides a promising sign for Forbes’ growth initiatives for its Consumer segment. For the full year, Consumer revenue grew an impressive 266% from $18 million to $66 million. Consumer includes subscription revenue from memberships to services such as Forbes Profiles as well as e-commerce. Consumer accounted for 25% of total revenue in 2021 compared with prior estimates by management that it would represent 12%. Management’s long-term expectation is that Consumer will account upwards of 38% of total revenue. As such, 2021 was meaningful step forward towards the company’s goal of growing the segment.

In addition to the strong revenue and EBITDA growth in 2021, the company generated its highest-ever free cash flow, at $43 million, representing free cash flow conversion of just over 70%. Post-merger, the company is expected to have $145 million in cash from investors and virtually no debt on the balance sheet. The cash from the transaction, together with the strong free cash flow generation, should provide flexibility to continue pursuing the company’s growth initiatives.

In February 2022, Forbes announced that cryptocurrency infrastructure provider, Binance, agreed to join the SPAC merger as one of the PIPE investors. Binance will account for $200 million of the $400 million in PIPE commitments. Notably, Binance Chief Communications Officer, Patrick Hillman and Head of Labs, Bill Chin will now be joining the Forbes Board of Directors, upon the completion of the SPAC merger. Binance will not only be an investor, but also a partner, as Binance’s expertise in blockchain technology can help Forbes continue to be a resource for investors interested in cutting-edge digital assets.

The 2021 operating results topped management’s forecasts for both 2021 and 2022. As such, the company will likely be revising estimates upwards for 2022 and 2023. However, management has not released new guidance yet. Therefore, for valuation purposes, we are applying management’s previously indicated growth rates to the full year 2021 reported revenue and adj. EBITDA to arrive at estimates for 2022 and 2023. The valuation detailed in this report assumes year-over-year revenue growth of 12% for both 2022 and 2023. Adj. EBITDA for 2022 and 2023 assumes growth of 20% and 25%, respectively. 

Figure #2 Forbes Peer Group highlights the company’s industry peers. The peer group consists of five different sectors in which the company operates: Publishers, Data Information, Media, Education, and Entertainment. The OPA shares trade at a discount when compared to the company’s peer group, based on upwardly revised estimates of adj. EBITDA of $72 million in 2022 and $90 million in 2023. The enterprise value calculation for Forbes is based on 83 million shares outstanding, proforma post-merger cash of $145 million, and no debt. Near current levels, the OPA shares trade at 9.5 times EV to 2022 EBITDA and 7.6 times EV to 2023 EBITDA. If the shares were to trade in line with the company’s peer group average of 16.7 times of 2022 EBITDA and 13.5 times of 2023 EBIDA, the shares would trade near $16, a 60% premium to current levels. Therefore we are revising our price target on the OPA shares from $14 to $16.

Figure #2 Forbes Peer Group



Source: TIKR and Noble Capital Markets

GENERAL DISCLAIMERS

All statements or opinions contained herein that include the words “we”, “us”, or “our” are solely the responsibility of Noble Capital Markets, Inc.(“Noble”) and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results.

Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.

IMPORTANT DISCLOSURES

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. (“Noble”). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst’s judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.

The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.

Company Specific Disclosures

The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.

Company Specific Disclosures

The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.

The SPAC Company in this report is a participant in the Company Sponsored Research Program (CSRP); Noble receives compensation from the Company for such participation. No part of the CSRP compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed by the analyst in this research report.

Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months

ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE

Director of Research. Senior Equity Analyst specializing in Media & Entertainment. 34 years of experience as an analyst. Member of the National Cable Television Society Foundation and the National Association of Broadcasters. BS in Management Science, Computer Science Certificate and MBA specializing in Finance from St. Louis University.
Named WSJ ‘Best on the Street’ Analyst six times.
FINRA licenses 7, 24, 66, 86, 87

WARNING

This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to Noble Capital Markets, Inc. by an investment advisor, that advisor may receive a benefit in respect of transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by Noble Capital Markets, Inc.. This report may not be reproduced, distributed or published for any purpose unless authorized by Noble Capital Markets, Inc.

RESEARCH ANALYST CERTIFICATION

Independence Of View
All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation
No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public
appearance and/or research report.

Ownership and Material Conflicts of Interest
Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.

NOBLE RATINGS DEFINITIONS % OF SECURITIES COVERED % IB CLIENTS
Outperform: potential return is >15% above the current price 99% 30%
Market Perform: potential return is -15% to 15% of the current price 7% 3%
Underperform: potential return is >15% below the current price 0% 0%

NOTE: On August 20, 2018, Noble Capital Markets, Inc. changed the terminology of its ratings (as shown above) from “Buy” to “Outperform”, from “Hold” to “Market Perform” and from “Sell” to “Underperform.” The percentage relationships, as compared to current price (definitions), have remained the same.

Additional information is available upon request. Any recipient of this report that wishes further information regarding the subject company or the disclosure information mentioned herein, should contact Noble Capital Markets, Inc. by mail or phone.

Noble Capital Markets, Inc.
150 East Palmetto Park Rd., Suite 110
Boca Raton, FL 33432
561-994-1191

Noble Capital Markets, Inc. is a FINRA (Financial Industry Regulatory Authority) registered broker/dealer.
Noble Capital Markets, Inc. is an MSRB (Municipal Securities Rulemaking Board) registered broker/dealer.
Member – SIPC (Securities Investor Protection Corporation)

Report ID: 24586

Salem Media Group (SALM) Scheduled to Present at NobleCon18 Investor Conference

Posted on by Admin

Salem Media Group EVP & CFO Evan Masyr provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


News and Advanced Market Data on SALM


About Salem Media Group

Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at www.salemmedia.com

PainReform (PRFX) Scheduled to Present at NobleCon18 Investor Conference

Posted on by Admin

PainReform CEO Ilan Hadar provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


News and Advanced Market Data on FLHLF


About PainReform

PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company’s lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company’s proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, please visit www.painreform.com.

The Case for More US Produced Uranium

Posted on by Admin 



  Image: Fronteras desk (Flickr)


The Good News and Bad News Surrounding US Uranium Self-Reliance

 

Is the Russia/Ukraine war providing cause to become more self-reliant producing reactor-grade uranium? Uranium can be mined in many parts of the world, but the processing that allows the reactive mineral to be used as fuel is done in just a few spots on the globe. Currently, a full 20% of electricity in the US is generated from nuclear fuel. Russia has a hand in the production of a lot of it.

 

Background

Enriched uranium is mined, milled, converted into a gas, then enriched to increase the percentage of the isotope to 3%-5% before rods for fuel can be created.

Each of the steps takes place at specialized facilities. Up until recently, with the reliance on nuclear power diminishing and decades of the power source largely being written out of the power production future, there was no incentive for companies along the U308 supply chain to grow their operations. And mining slowed as raw uranium prices were seen as too low to compete with cheaper imports.

Russian uranium enrichment accounts for around 35% of the global market. In fact, the only commercial plants for uranium conversion into gas are in Russia, France, and Canada. There was a plant operating in Illinois that was mothballed but is scheduled to rejoin this part of the uranium supply chain in 2023.

 

Price Increase

Russia enriches more uranium for use in nuclear plants than any other country. Russia’s invasion of neighboring Ukraine has shaken the global market, as sanctions, and potential sanctions have increased the scarcity of many resources, including uranium. The risk to US energy generation of relying on all or part of the production to be outside North America has suddenly become apparent. Talk of ramping up domestic production has increased, but it can’t occur overnight.

 

Using $URA as price proxy, Price increase since January 27, 2022

 

Uranium prices have risen more than 30% since the start of the war, and 40% since the beginning of the threat. Each part of the refining process, from mining the raw material to the enriching processes have experienced price increases.

While further sanctions cause utilities to lock in future needs, a trade agreement has been in place that limits US dependence on Russian uranium to no more than around 20% of domestic reactors demand. That is certainly better than a much higher percentage as the US isn’t fully reliant.  But no other country could quickly fill Russia’s role in the supply chain for US usage. Another positive is US plants generally refuel every 18 to 24 months and plan for this at least two to three years in advance. So there is little concern in the short run for existing plants running out. There is time to prepare.

 

Opportunity

Does this create an opportunity in the stock market? Many of the forces that are weighing on some sectors of the stock market are having a positive impact on North American uranium mining stocks.

There are a number of companies that are involved in uranium production that were becoming interesting before the recent supply chain problems related to the Russian invasion. The segment was getting much attention as a result of the plans of companies to build modern, smaller nuclear reactors. The sudden change in the market landscape has now caused some of these companies’ stocks to experience price increases well in excess of that of physical uranium or uranium futures contracts.

 

 

One such company is Energy Fuels (UUUU). Energy Fuels is the largest uranium producer in the US and holds more production capacity and uranium resources than any other US producer. The current market cap is $1.6 billion. The movement on UUUU for the same period that Uranium ran up near 40%, has pushed the stock price of this producer up near 80% since late January.

On March 17, Noble Capital Markets Senior Energy Analyst Michael Heim released a report on $UUUU titled Ramp Up is Coming Slowly but
Higher Prices Could Spur Activity. The report profiles the analyst’s view on the company and prospects in light of the changing market.

 

Take-Away

Uranium investments, whether a trust, a producer, or an ETF that tracks uranium prices have all been seeing an upsurge in interest. Part of this has been the move toward non-carbon-based energy and new generation modular plants being built.

The current understanding of how vulnerable the US is as a result of its offshoring much of the acquisition and processes to produce nuclear fuel, is likely to reshuffle where US plants fulfill most of their need in years to come. And those needs are expected to be increasing.

Channelchek is a great resource to analyze companies involved in this mining and energy segment. No cost sign-up provides full access to the website and research, including videos specific to uranium producers.

 

Suggested Reading



Has Uranium Demand Changed with Russia Ukraine War?

Is it Too Late to Benefit from Higher Oil?





Uranium and Natural Gas Investments Turn Green in 2023

Investor Information on Three Segments of the Uranium Energy Sector

 

Sources

https://www.uxc.com/p/products/spl_cesa.aspx

https://www.wsj.com/articles/u-s-rethinks-uranium-supply-for-nuclear-plants-after-russias-invasion-of-ukraine-11647941401

https://www.eia.gov/energyexplained/nuclear/where-our-uranium-comes-from.php

https://tradingeconomics.com/commodity/uranium

 

Stay up to date. Follow us:

 

electroCore to Present at 2022 Maxim Virtual Growth Conference

Posted on by Admin



electroCore to Present at 2022 Maxim Virtual Growth Conference

News and Market Data on electroCore

 

ROCKAWAY, N.J., 
March 22, 2022 (GLOBE NEWSWIRE) — 
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer,  Dan Goldberger, will be presenting at the 2022 
Maxim Virtual Growth Conference.

electroCore’s presentation will be available on-demand from 
March 28th – 30th, 2022. To view the presentation, click HERE.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

Investors:
Rich Cockrell

CG Capital
404-736-3838
ecor@cg.capital

Delta Air Lines Signs 75 Million Gallon Per Year Agreement with Gevo

Posted on by Admin



Delta Air Lines Signs 75 Million Gallon Per Year Agreement with Gevo

Research, News, and Market Data on Gevo

 

ENGLEWOOD, Colo., March 22, 2022 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) has signed a “take-or-pay” agreement with Delta Air Lines, Inc. (NYSE: DAL) to supply 75 million gallons of sustainable aviation fuel (SAF) per year for seven years (the “Agreement”). Based on current assumptions, including those around future pricing of commodities and the future values of certain environmental benefits, Gevo estimates that the Agreement should generate approximately $2.8 billion of revenue, inclusive of the value from environmental benefits, for Gevo over the seven-year term of the Agreement.

The Agreement replaces the existing agreement signed with Delta in 2019 to purchase 10 million gallons per year and bolsters Delta’s commitment to incorporating SAF into its operations.

“On behalf of the entire team at Gevo, I want to congratulate our partners at Delta for their leadership in continuously pushing the aviation industry towards net-zero emissions. Delta makes for a great customer, recognizing that big change is needed. I also appreciate their faith in what we are doing at Gevo. Net-zero jet fuels matter. We expect production from our first Net-Zero plant to begin in 2025. To meet the demand that we now have under contract, we need to develop and build more than one Net-Zero plant. This is a happy problem to have,” said Patrick R. Gruber, Ph.D., Gevo’s Chief Executive Officer.

“Net-Zero Fuels are made by using low-carbon feedstocks produced with climate-smart agricultural practices and by eliminating fossil-based energy from the business system as much as possible. In addition, our customers depend on us to count carbon at every step of the process,” said Paul D. Bloom, Ph.D., Gevo’s Chief Carbon Officer, and Chief Innovation Officer. Dr. Bloom continued, “By accurately accounting for carbon emissions using Argonne National Laboratories GREET model along with our Verity Tracking platform we will provide confidence to our customers like Delta that scientifically robust and transparent methods are used to meet and measure their sustainability goals. We want to create a win-win value proposition for every participant in the SAF supply chain by tracking all carbon intensity benefits in our SAF.”

“SAF is a critically important lever we have available today to help our industry reduce the lifecycle carbon emissions from aviation fuel,” said Kelly Nodzak, Delta’s Director of Global Jet Fuel Procurement. “That’s why we are working to develop the market and a broader understanding of the effectiveness of SAF, which can reduce lifecycle emissions up to 80 percent when used in pure form compared to fossil jet fuels.”

“With the right policies and incentives in place, we can unlock a future where sustainable aviation fuel is a viable climate solution that benefits air travel and beyond,” said Amelia DeLuca, Delta’s Vice President of Sustainability. “SAF production creates good-paying jobs in manufacturing, improves the environmental quality for all, and fosters rural economic opportunity for feedstocks and pathways. It will help us protect the planet we share and the places we call home.”

Gevo has remained focused on sustainability at every stage of production. Gevo has developed two alcohol-to-jet pathways that can utilize various low-carbon feedstocks grown using sustainable agriculture. These feedstocks can then be converted, in some cases, to high-value nutritional products and energy-dense liquid hydrocarbons, including SAF. Gevo’s production processes will incorporate renewable energy, including wind turbines, biogas, and combined heat and power systems (CHP) to increase efficiency and reduce carbon intensity to net-zero levels, which the customer can then pass on through the fuel.

The Agreement is subject to certain conditions precedent, including Gevo developing, financing and constructing one or more production facilities to produce the SAF contemplated by the Agreement. A copy of the Agreement between Delta and Gevo has been filed with the U.S. Securities and Exchange Commission on Form 8-K.

About Gevo

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel, and diesel fuel, that when burned, have the potential to yield net-zero greenhouse gas emissions when measured across the full life cycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their life cycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low-carbon products such as gasoline components, jet fuel, and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Learn more at Gevo’s website: www.gevo.com

About Delta Air Lines

Delta’s commitment to sustainability is about joining arms to create a better world. The airline’s ambitious commitment to carbon neutrality from March 2020 onward is coming to fruition with swift impact through immediate actions, coupled with long-term investments to combat climate change. These investments will drive innovation, advance clean air travel technologies, accelerate the reduction of carbon emissions and waste, and establish a path to a more sustainable future. As a company driven by purpose, we hold ourselves to a high standard of producing sustainable, responsible financial results while investing in healthy communities, maintaining a diverse and inclusive workforce, and protecting natural environments. These values drive our overall approach to Environmental, Social, and Governance (ESG) sustainability and responsibility.

Learn more at the Delta Air Lines website: www.delta.com/

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, without limitation, including the Agreement, Delta’s purchase of SAF from Gevo, Gevo’s ability to produce SAF, Gevo’s estimate of the revenue that might be generated from the Agreement, Gevo’s ability to produce SAF and other fuels with a net-zero carbon intensity, Gevo’s technology, Gevo’s development, financing and construction of production facilities to produce SAF, the attributes of Gevo’s products, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2021, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

Gevo Investor and Media Contact

Heather L. Manuel

+1 720-418-0085

IR@gevo.com

Tonix Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Posted on by Admin



Tonix Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Research, News, and Market Data on Tonix Pharmaceuticals

 

CHATHAM, N.J., March 22, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest.

The conference will take place March 28-30, 2022, with pre-recorded presentations available on-demand through the conference portal at 2022 Virtual Growth Conference and available under the IR Events tab of the Tonix website at www.tonixpharma.com. This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member here: Reserve Your Seat.

About Tonix Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, central nervous system (CNS) and infectious disease product candidates. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL2, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug in mid-Phase 3 development for the management of fibromyalgia, with a new Phase 3 study expected to start in the first half of 2022. TNX-102 SL is also being developed to treat Long COVID, a chronic post-COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the first half of 2022. TNX-13003 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the first half of 2022. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer. Tonix’s lead immunology candidate, TNX-15001, is a humanized monoclonal antibody targeting CD40 ligand being developed for the prevention of allograft rejection and the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to start in the second half of 2022. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox, next-generation vaccines to prevent COVID-19 and an antiviral to treat COVID-19. Tonix’s lead vaccine program is TNX-801 (live horsepox virus for percutaneous administration) for preventing smallpox and monkeypox4. Horsepox is also the basis for Tonix’s recombinant pox vaccine (RPV) platform. Tonix’s lead vaccine candidates for COVID-19, TNX-1840 and TNX-18505, are live virus vaccines in development based on the RPV platform. Finally, TNX-35006 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development.

1TNX-1500 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.

2TNX-102 SL is an investigational new drug and has not been approved for any indication.

3TNX-1300 is an investigational new biologic and has not been approved for any indication.

4TNX-801 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.

5TNX-1840 and TNX-1850 are investigational new biologics at the pre-IND stage of development and have not been approved for any indication. TNX-1840 and TNX-1850 are designed to express the spike protein of SARS-CoV-2 from omicron and BA.2 variants, respectively, based on the experience from TNX-1800, which expresses the spike protein from the ancestral Wuhan strain.

6TNX-3500 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Source: Tonix Pharmaceuticals Holding Corp.

Comstock Announces Notice of 2021 Year End Webcast

Posted on by Admin



Comstock Announces Notice of 2021 Year End Webcast

Research, News, and Market Data on Comstock Mining

 

VIRGINIA CITY, Nev., March 22, 2022 (GLOBE NEWSWIRE) — Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced that it will host a conference call on Tuesday, March 29, 2022, at 8:00 a.m. Pacific Daylight Time (11:00 a.m. Eastern Daylight Time) to report its 2021 Year End results and provide a business update. The webcast will include a moderated question and answer session after the Company’s prepared remarks. Please click the link below to register in advance and join the event 10 to 15 minutes prior to the scheduled start time. After registering, you will receive a confirmation email containing information about joining the Webcast.

March 29, 2022, 08:00 AM Pacific Daylight Time / 11:00 AM Eastern Daylight Time (US and Canada)

Topic: Comstock’s Year End 2021 Results and Business Update

Please click here to register in advance for this webcast.

About Comstock Mining Inc.
Comstock Mining Inc. (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting massive supplies of under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complimentary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstockmining.com.

Forward-Looking Statements
This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future changes in our research and development; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; and future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, taxes, earnings and growth. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in reports that we file with the Securities and Exchange Commission, including Item 1A, “Risk Factors” in our most recently-filed Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, mercury remediation and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration or mercury remediation, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with mercury remediation, metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; ability to achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology, mercury remediation technology and efficacy, quantum computing and advanced materials development, and development of cellulosic technology in bio-fuels and related carbon-based material production; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither this press release nor any related call or discussion constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

Contact information:    
Comstock Mining Inc.
P.O. Box 1118
Virginia City, NV 89440
ComstockMining.com		 Corrado De Gasperis
Executive Chairman & CEO
Tel (775) 847-4755
degasperis@comstockmining.com		 Zach Spencer
Director of External Relations
Tel (775) 847-5272 Ext.151
questions@comstockmining.com

BioSig Technologies, Inc. Announces $3 Million Financing with Family Office

Posted on by Admin



BioSig Technologies, Inc. Announces $3 Million Financing with Family Office

News and Market Data on BioSig Technologies

 

Westport, CT, March 22, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it entered in a definitive purchase agreement for the sale of  $3 million of the Company’s common stock and warrants lead by a family office that has deep expertise in small cap emerging growth investing.  The closing of the offering is expected to occur on or about March 23, 2022, subject to the satisfaction of customary closing conditions.

Under the terms of the financing agreement, the Company will issue 2,611,739 shares of its common stock at a price of $1.15 per share and warrants to purchase 2,611,739 shares of the Company’s common stock at $1.40 per share.

BioSig intends to use the net proceeds from the offering to fund working capital and continue commercialization activities related to the PURE EP™ System.  This funding and its existing capital should provide sufficient operating capital for BioSig to execute its current business plan.

The offering is being made only by means of a prospectus supplement and accompanying base prospectus. The Company has filed a shelf registration on Form S-3 (File No. 333-251859) (including a base prospectus) with the U.S. Securities and Exchange Commission (“SEC”), which was declared effective on January 12, 2021. A final prospectus supplement and accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying base prospectus for the offering may also be obtained, when available, by contacting BioSig Technologies, Inc., 55 Greens Farms Road, Westport, CT 06880, Attention: Lora Mikolaitis; lmikolaitis@biosigtech.com. 

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the closing of the offering, (ii) the use of proceeds for the offering, (iii) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (iv) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (v) difficulties in obtaining financing on commercially reasonable terms; (vi) changes in the size and nature of our competition; (vii) loss of one or more key executives or scientists; and (viii) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119

Source: BioSig Technologies, Inc.